Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar ? ARO-INHBE and ARO-ALK7 Interim Clinical Data ? January 6, ...

PASADENA, Calif., December 15, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, ...

Arrowhead Pharmaceuticals, Inc, a global company develops medicines to treat intractable diseases by silencing the genes that cause them, announced that it has dosed the first subjects in a phase 1/2a ...

- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-barrier - Study initiation further ...

A University of Maryland, Baltimore County (UMBC) study, published in Nature Communications, uncovers how enteroviruses—including those causing polio, myocarditis, encephalitis, and the common ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

This study systematically elucidates the drug resistance mechanisms of five highly pathogenic viruses, proposes five ...

Gov. Maura Healey is expected to be in Norton Wednesday morning to announce some good news: a $250 million expansion of a manufacturing plant run by Alnylam Pharmaceuticals, a publicly traded biotech ...

Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has ...